ARQL ArQule Inc.

1.11
+0.03  (2%)
Previous Close 1.08
Open 1.07
Price To book 7.89
Market Cap 78644564
Shares 71,171,551
Volume 298,167
Short Ratio 2.74
Av. Daily Volume 163,126

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171138298
  2. 8-K - Current report 171137673
  3. 8-K - Current report 171112400
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171007461
  5. 8-K - Current report 171006893

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial has commenced enrollment - May 4, 2017.
ARQ 092
Overgrowth Diseases
Phase 2 data at ASCO June 3, 2017 - ORR 21%. Phase 3 trial planned for 3Q 2017.
ARQ 087
intrahepatic cholangiocarcinoma (iCCA)
Phase 3 top-line data released February 17, 2017 - primary endpoint not met.
Tivantinib (ARQ 197) METIV-HCC trial
Previously treated Inoperable Hepatocellular Carcinoma cancer

Latest News

  1. ArQule Announces $15.7 Million Private Placement of Common Stock
  2. ArQule to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26, 2017
  3. Edited Transcript of ARQL earnings conference call or presentation 4-Aug-17 1:00pm GMT
  4. ArQule reports 2Q loss
  5. ArQule Reports Second Quarter 2017 Financial Results
  6. Investor Network: ArQule, Inc. to Host Earnings Call
  7. ArQule To Report Second Quarter 2017 Financial Results On August 4, 2017
  8. ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies
  9. SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ArQule, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
  10. ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)
  11. ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases
  12. ArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
  13. ArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)
  14. ArQule to Present Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
  15. Edited Transcript of ARQL earnings conference call or presentation 3-May-17 1:00pm GMT
  16. Arqule Reports First Quarter 2017 Financial Results
  17. ArQule Announces Issuance of U.S. Patent Covering Composition of Matter of Proprietary Reversible BTK Inhibitor, ARQ 531
  18. ArQule To Report First Quarter 2017 Financial Results On May 3, 2017

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171138298
  2. 8-K - Current report 171137673
  3. 8-K - Current report 171112400
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171007461
  5. 8-K - Current report 171006893
  6. 8-K - Current report 17982874
  7. 8-K - Current report 17866487
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 17807744
  9. 8-K - Current report 17807174
  10. DEF 14A - Other definitive proxy statements 17759305